inno-406 and benzamide

inno-406 has been researched along with benzamide* in 2 studies

Other Studies

2 other study(ies) available for inno-406 and benzamide

Article	Year
Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorganic & medicinal chemistry letters, 2007, May-15, Volume: 17, Issue:10 To investigate why 3-substituted benzamide derivatives show dual inhibition of Abl and Lyn protein tyrosine kinases, we determined their inhibitory activities against Abl and Lyn, carried out molecular modeling, and conducted a structure-activity relationship study with the aid of a newly determined X-ray structure of the Abl/Lyn dual inhibitor INNO-406 (formerly known as NS-187) bound to human Abl. We found that this series of compounds interacted with both kinases in very similar ways, so that they can inhibit both kinases effectively. Topics: Benzamides; Enzyme Inhibitors; Humans; Molecular Conformation; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Structure-Activity Relationship	2007
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorganic & medicinal chemistry letters, 2006, Mar-01, Volume: 16, Issue:5 A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship	2006

Article

Year

Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.

Bioorganic & medicinal chemistry letters, 2007, May-15, Volume: 17, Issue:10

To investigate why 3-substituted benzamide derivatives show dual inhibition of Abl and Lyn protein tyrosine kinases, we determined their inhibitory activities against Abl and Lyn, carried out molecular modeling, and conducted a structure-activity relationship study with the aid of a newly determined X-ray structure of the Abl/Lyn dual inhibitor INNO-406 (formerly known as NS-187) bound to human Abl. We found that this series of compounds interacted with both kinases in very similar ways, so that they can inhibit both kinases effectively.

Topics: Benzamides; Enzyme Inhibitors; Humans; Molecular Conformation; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Structure-Activity Relationship

2007

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.

Bioorganic & medicinal chemistry letters, 2006, Mar-01, Volume: 16, Issue:5

A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia.

Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship

2006